Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03659448 · ClinicalTrials.gov registry record · Phase 3
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
A Phase 3 study of Colorectal Neoplasms, sponsored by Surgimab.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 11
- Study locations
NCT03659448 is a Phase 3 study of Colorectal Neoplasms that is actively recruiting participants, run by Surgimab. The registered enrollment target is 300 participants, below the 571-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (47% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT03659448, a Phase 3 study of Colorectal Neoplasms, is actively recruiting participants, sponsored by Surgimab.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 11
- Study locations
Study Summary
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Conditions Studied
Interventions
- DRUG SGM-101
Study Locations (11)
Other
- Universitätsmedizin Göttingen, Klinik für Allgemein- Viszeral- und Kinderchirurgie - Göttingen
- Catharina Ziekenhuis Eindhoven - Eindhoven
- Leiden University Medical Center - Leiden
- Erasmus MC - Rotterdam
California
- City of Hope National Medical Center - Duarte
- Moores Cancer Center - UCSD Health - La Jolla
Massachusetts
- Massachusetts General Hospital - Boston
- University of Massachusetts - Worcester
Florida
- Cleveland Clinic Florida - Weston
Pennsylvania
- Perelman Center for Advanced Medicine - Philadelphia
Lombardy
- Fondazione IRCCS Policlinico San Matteo - Pavia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2024-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03659448
The ClinicalTrials.gov registry entry for NCT03659448 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 571-participant average among 54 other Colorectal Neoplasms trials with a reported enrollment target (47% lower). The listed sponsor is Surgimab, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which SGM-101 is the first listed.
NCT03659448 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03659448 about?
NCT03659448 is a clinical study titled "Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer". The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
What is the current status of trial NCT03659448?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2019-06-17. Estimated completion is 2024-12.
What conditions does trial NCT03659448 study?
This clinical trial studies the following conditions: Colorectal Neoplasms.
What interventions are being tested in trial NCT03659448?
The interventions under investigation include: SGM-101 (DRUG).
Who is sponsoring clinical trial NCT03659448?
This trial is sponsored by Surgimab, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03659448 being conducted?
This trial has 11 study locations across California, Florida, Massachusetts, Pennsylvania, Lombardy. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
RECRUITING · Phase 3
-
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 3
-
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
RECRUITING · Phase 3
-
S0820, Adenoma and Second Primary Prevention Trial
ACTIVE NOT RECRUITING · Phase 3
-
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.